title: Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement.
abstract: BACKGROUND
  Lipoprotein associated phospholipase A2 (Lp-PLA2) is a novel biomarker for cardiovascular risk prediction. Whether increased Lp-PLA2 level is associated with re-stenosis after stent-placement is unclear.
  
  
  METHODS
  Totally 326 participants eligible for stent-placement were enrolled and divided into two groups according to baseline Lp-PLA2 levels (named normal and elevated groups). Baseline characteristics and clinical outcomes were compared between normal and elevated groups. The relationships between Lp-PLA2 and other risk factors with re-stenosis were evaluated.
  
  
  RESULTS
  Only the between-group difference of Lp-PLA2 was significant (123.2 ± 33.6 ng/mL vs 336.8 ± 85.4 ng/mL, P < 0.001) while other demographic and clinical characteristics between these two groups were comparable. Approximately 55.1% and 58.5% of participants in normal and elevated groups presented with acute coronary syndrome, and the percentage of tri-vessels stenoses was significantly higher in elevated group (40.8% vs 32.1%, P = 0.016). Nearly 96.0% and 94.0% of participants in normal and elevated Lp-PLA2 groups were placed with drug-eluting stents, and the others were with bare-metal stents. After 1 year's follow-up, the incidence of clinical end-points was comparable (13.3% vs 15.4%, P = 0.172). Nevertheless, the incidence of re-stenosis was marginally higher in elevated Lp-PLA2 group (8.5% versus 4.6%, P = 0.047). With multivariate analysis, after adjustment for other risk factors, Lp-PLA2 remained an independent predictor for re-stenosis with a hazard ratio of 1.140. No synergistic effect between Lp-PLA2 and other risk factors for re-stenosis was found.
  
  
  CONCLUSIONS
  Increased Lp-PLA2 level is associated with an increased risk of re-stenosis. Lp-PLA2 assessment may be useful in predicting subjects who are at increased risk for re-stenosis.
authors.forename: Dongdan
authors.initials: D
authors.lastname: Zheng
authors.forename: FanFang
authors.initials: F
authors.lastname: Zeng
authors.forename: Anping
authors.initials: A
authors.lastname: Cai
authors.forename: Huocheng
authors.initials: H
authors.lastname: Liao
authors.forename: Ling
authors.initials: L
authors.lastname: Liu
authors.forename: Ruofeng
authors.initials: R
authors.lastname: Qiu
authors.forename: Rulin
authors.initials: R
authors.lastname: Xu
authors.affiliation: Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Road 2, Guangzhou 510080, China. HuizhouXiaoc@163.com.
authors.forename: Chun
authors.initials: C
authors.lastname: Xiao
authors.forename: Weiyi
authors.initials: W
authors.lastname: Mai
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood*; D000368:Aged; D003324:Coronary Artery Disease / Q000097:blood / Q000201:enzymology* / Q000401:mortality / Q000601:surgery; D023903:Coronary Restenosis / Q000097:blood / Q000201:enzymology* / Q000401:mortality / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D012307:Risk Factors; D015607:Stents; D016896:Treatment Outcome
chemical_list: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase